<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652375</url>
  </required_header>
  <id_info>
    <org_study_id>2000025462</org_study_id>
    <nct_id>NCT04652375</nct_id>
  </id_info>
  <brief_title>Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures</brief_title>
  <official_title>Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blinded study to compare the use of albumin versus&#xD;
      lactated Ringer's solution in patients undergoing coronary artery bypass graft surgery and in&#xD;
      patients undergoing aortic valve replacement surgery and evaluate the incidence of acute&#xD;
      kidney injury as a primary outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, randomized, double-blinded study to compare the use of albumin&#xD;
      versus lactated Ringer's solution in patients undergoing coronary artery bypass graft surgery&#xD;
      and in patients undergoing aortic valve replacement surgery and evaluate the incidence of&#xD;
      acute kidney injury as a primary outcome. Data will be collected from both EPIC and STS&#xD;
      (society of thoracic surgeons) database. STS database extracts data from the electronic&#xD;
      medical record and groups it in specific format to evaluate outcomes after cardiac surgery to&#xD;
      compare institutional performance to similar institutions and the national average. Patients&#xD;
      undergoing coronary artery bypass graft or aortic valve replacement will be randomized to&#xD;
      receive either albumin or lactated Ringer's for fluid resuscitation post-surgery. The&#xD;
      resuscitation volume will be based on clinical decision after examining all the hemodynamics&#xD;
      parameters. This practice coincides with standard of care and current practice. All eligible&#xD;
      patients will be randomly assigned to receive either albumin 5% or lactated Ringer's solution&#xD;
      in a 1:1 ratio using computer-generated, permutated blocks of 2 - 4. Both solutions will be&#xD;
      administered intravenously in 250 mL increments at the discretion of the physician until&#xD;
      hemodynamic parameters are met. The IV infusion bag and IV tubing will be covered using&#xD;
      opaque bags to allow for blinding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>Within 72 hours post randomization</time_frame>
    <description>Acute kidney injury will be assessed by these criteria: Stage I. Increase 1.5-1.9 times from baseline or ≥ 0.3 mg/dl increase within 48 h. Urinary output (UOP) &lt; 0.5 ml/kg/h for 6-12 hours Stage II. Increase &gt; 2- to 3-fold from baseline. UOP &lt; 0.5 ml/kg/h for 12 hours Stage III. Increased &gt; 300% (&gt; 3-fold) from baseline, or ≥ 4.0 mg/dl with an acute increase of ≥ 0.5 mg/dl or on renal replacement therapy. UOP &lt; 0.3 ml/kg/h for 24 hours or anuria for 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extubation time</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Duration of intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Length of stay in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Length of stay in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission</measure>
    <time_frame>Readmission within 30 days of discharge</time_frame>
    <description>An episode when a patient who had been discharged from a hospital is admitted again within a specified time interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <condition>Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Albumin Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Albumin solution for fluid resuscitation post-surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringer's Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lactated Ringer's for fluid resuscitation post-surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Albumin Solution</intervention_name>
    <description>Participants will receive Albumin solution for fluid resuscitation post-surgery.</description>
    <arm_group_label>Albumin Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactated Ringer's Solution</intervention_name>
    <description>Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.</description>
    <arm_group_label>Lactated Ringer's Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients greater than 18 years of age undergoing CABG and AVR procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low ejection fraction (&lt;20%) End stage renal disease Chronic renal insufficiency&#xD;
             Pre-operative Inotropic (eg. Dobutamine) or vasoactive IV infusions (e.g,&#xD;
             norepinephrine)&#xD;
&#xD;
               -  Jehovah's Witness Emergent surgery (e.g, intra-aortic balloon pump) Pre-operative&#xD;
                  acute kidney injury based on AKIN criteria Non English speaking patients&#xD;
&#xD;
               -  Jehovah's Witness population will be excluded regardless of their preference with&#xD;
                  accepting Albumin because sometimes PRBC are used as part of ongoing&#xD;
                  resuscitation in bleeding patients and if patients cannot use blood, this will&#xD;
                  have a much bigger issue with resuscitation and this study is not designed to&#xD;
                  follow up that population.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossam Tantway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hossam Tantawy, MD</last_name>
    <phone>203-785-2802</phone>
    <email>hossam.tantawy@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Kampp, BS</last_name>
    <phone>203-737-5118</phone>
    <email>michael.kampp@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

